LAURA SPASIC: Open Payments
NPI 1588970974 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,038 in 57 payments from 14 companies in 2025. Trend: 2023 $1,038 · 2024 $1,065 · 2025 $1,038
Food & beverage: $1,038
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 12 | $178 |
| Axsome Therapeutics, Inc. | 5 | $151 |
| ABBVIE INC. | 10 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $118 |
| Novo Nordisk Inc | 5 | $84 |
| GlaxoSmithKline, LLC. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $62 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
Products named: MOUNJARO, Auvelity, AIRSUPRA, TRELEGY ELLIPTA, VRAYLAR, CAPLYTA, FANAPT, Ozempic.
Industry payments across OH — which companies pay providers there.
